{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:52:02Z","timestamp":1767761522753,"version":"3.48.0"},"reference-count":10,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High\u2010degree atrioventricular block (AVB) and permanent pacemaker (PPM) implantation remain common complications following transcatheter aortic valve replacement (TAVR). Limited evidence exists on whether early postprocedural administration of atrioventricular (AV) nodal blocking medications impacts these outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the safety of AV nodal blocker use within the first 48\u2009h after TAVR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted in adults who underwent TAVR from January 1, 2016 to April 2, 2024. The population was divided into two cohorts based on administration of an AV nodal blocker within the first 48\u2009h. The primary endpoint was the rate of second\u2010degree or higher AVB at 30 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 756 patients met the study criteria, with 381 (50.4%) receiving an AV nodal blocker within 48\u2009h. The primary outcome occurred in 2.7% of patients who did not receive an AV nodal blocker and 1.6% of those who did (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.297). No significant difference was observed in second\u2010degree or higher AVB at discharge, PPM placement at 30 days, or hospital length of stay. All\u2010cause mortality at 30 days was significantly higher in the AV nodal blocker group (2.4% vs. 0.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011), but this difference did not remain significant after adjusting for covariates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AV nodal blocker use within 48\u2009h following TAVR was not associated with an increased rate of second\u2010degree or higher AVB or PPM placement. These findings suggest that AV nodal blockers may be considered in the immediate post\u2010TAVR period based on risk\u2010benefit assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ccd.70357","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T19:21:23Z","timestamp":1763666483000},"page":"351-356","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Early Atrioventricular Nodal Blocker Use Post\u2010Transcatheter Aortic Valve Replacement"],"prefix":"10.1002","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4943-5191","authenticated-orcid":false,"given":"Jocelyn","family":"Edwards","sequence":"first","affiliation":[{"name":"University of North Carolina Medical Center Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Carroll","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikayla","family":"Lovelace","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorden","family":"Mandel","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Carter","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Kline","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Premarket Approval (PMA) accessed July 29 2024 https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P100041."},{"key":"e_1_2_9_3_1","unstructured":"Commissioner of the FDA Expands Indication for Several Transcatheter Heart Valves to Patients at Low Risk for Death or Major Complications Associated With Open\u2010Heart Surgery. FDA. Published March 24 2020 accessed July 29 2024 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-indication-several-transcatheter-heart-valves-patients-low-risk-death-or-major."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000923"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2020.09.002"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx785"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2020.09.063"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2020-001269"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.28017"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.29239"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2024.03.034"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.70357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:42:27Z","timestamp":1767760947000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.70357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/ccd.70357"],"URL":"https:\/\/doi.org\/10.1002\/ccd.70357","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"type":"print","value":"1522-1946"},{"type":"electronic","value":"1522-726X"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"2025-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}